Seek Returns

ARGX vs. LLY: argenx vs. Eli Lilly Stock Comparison

How do argenx (ARGX) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Eli Lilly (LLY) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Eli Lilly (LLY)
Profile ItemARGXLLY
Nameargenx SE American Depositary ReceiptEli Lilly and Company
Country/RegionNetherlandsUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization58.31 billion USD1,206.07 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 18, 2017June 1, 1972
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

ARGX
LLY
GSPC
Loading price history…
argenx (ARGX) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for argenx (ARGX) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for argenx (ARGX) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
Total Return (1Y)11.91%52.36%
Total Return (3Y, Annualized)25.68%34.18%
Total Return (5Y, Annualized)24.22%41.08%

Risk Profile

Drawdown History

ARGX
LLY
GSPC
Loading price history…
argenx (ARGX) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for argenx (ARGX) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
Volatility (1Y, Annualized)37.87%35.34%
Beta (5Y)0.450.40
Max Drawdown (5Y)-38.20%-34.48%
Avg. Volume (3M)359.84K2.52M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ARGX and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
Sharpe Ratio (1Y)0.201.36
Sortino Ratio (1Y)0.312.29

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Eli Lilly (LLY) earns 86.02% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ARGX
--

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max
109.18%
LLY
86.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): ARGX does not report ROE, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both argenx (ARGX) at 31.73% and Eli Lilly (LLY) at 31.90% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX
31.73%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY
31.90%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both argenx (ARGX) at 36.27% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max
83.12%
ARGX
36.27%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max
83.12%
LLY
53.66%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
ROE (TTM)--86.02%
ROA (TTM)--21.06%
Net Margin (TTM)31.73%31.90%
Operating Margin (TTM)36.27%53.66%
Gross Margin (TTM)59.84%83.63%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Eli Lilly (LLY) at 44.70% is closer to the peer norm — faster top-line expansion for ARGX.

Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while argenx (ARGX) at 53.13% is closer to the peer norm — faster per-share earnings growth for LLY.

Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
Revenue Growth (YoY)89.64%44.70%
Revenue Growth (3Y CAGR)116.25%31.69%
EPS Growth (YoY)53.13%95.99%
EPS Growth (3Y CAGR)--51.71%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Eli Lilly (LLY) shows current ratio of 1.39 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
ARGX
--

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
LLY
1.39
Min
0.10
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): ARGX does not report current ratio, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
ARGX
0.01
Min
0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max
1.42
LLY
1.23
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
Current Ratio (MRQ)--1.39
Debt / Equity (MRQ)0.011.23
Net Debt / EBITDA-2.700.96

Dividends

Dividend Yield (TTM)

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY
0.49%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

argenx (ARGX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY
21.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
Dividend Yield (TTM)0.00%0.49%
Dividend Payout Ratio (TTM)0.00%21.71%

Valuation

P/E Ratio (TTM)

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max
85.34
Q3
43.46
ARGX
32.12
Median
26.69
Q1
13.30
Min
0.07

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max
85.34
LLY
43.95
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max
58.18
Q3
25.77
ARGX
9.86
Median
7.30
Q1
3.01
Min
0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max
58.18
Q3
25.77
LLY
13.95
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both argenx (ARGX) at 172.23 and Eli Lilly (LLY) at 29.96 look expensive — each P/B ratio sits above its industry’s benchmark range.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX
172.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY
29.96
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
argenx (ARGX) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Eli Lilly (LLY)
MetricARGXLLY
P/E Ratio (TTM)32.1243.95
P/S Ratio (TTM)9.8613.95
P/B Ratio (MRQ)172.2329.96
Free Cash Flow Yield (TTM)--0.77%